New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements

- September 17th, 2018

Daxor (NYSE MKT:DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over surrogate measurements, including cardiac filling pressure and kidney … Continued

Daxor (NYSE MKT:DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over surrogate measurements, including cardiac filling pressure and kidney function.

As quoted in the press release:

“In each study, we compared blood volume analysis to a surrogate marker to understand the best way to treat heart failure and, in one study, heart failure with accompanying kidney disease. Both studies demonstrated that accurate blood volume measurement provided important information for physicians to better treat individual cases of fluid overload and potentially reduce additional complications,” said Wayne L. Miller, M.D., Ph.D., Mayo Clinic, who was the lead author of both studies. “Both of these posters underscore the value of accurate blood volume measurement as a means of reducing mortality in this complex to treat patient population.”

One poster, “Volume and Pressure in Heart Failure – Complimentary, But Not Two Sides of the Same Coin,” showed the distinction between blood volume analysis and cardiac volume pressure (CVP), which is a surrogate marker for fluid volume expansion and overload in heart failure patients. The study concludes that while both demonstrate value, there is no substitute for clear measurement of fluid volume, as CVP does not accurately reflect volume status, and therefore should be an additional measure to blood volume analysis rather than a substitute when making treatment decisions in heart failure patients with potential volume overload. The second poster, “Volume-Kidney Interaction in Chronic Heart Failure – Impact of Subclinical Volume Expansion and Chronic Kidney Disease on Clinical Outcomes,” showed that blood volume has a direct connection with kidney function, demonstrating additional risk in patients with both heart failure and impaired kidneys. Use of the BVA-100 provided investigators with accurate plasma volume measurement in order to assess total risk.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *